A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Trial Details

NCT ID

NCT07229729

Phase

PHASE2

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

• SHR-A2102
• Adebrelimab
• Paclitaxel
• Carboplatin
• Alomnertinib Mesilate
• Furmonertini Mesilate

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• Voluntarily participate in this clinical study, understand the research procedures and be able to sign the informed consent form in writing;
• Participants must be aged between 18 and 70 years old (inclusive) when signing the informed consent form, and both men and women are eligible;
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
• Adequate organ function;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.